Sapu Nano to Present Everolimus Toxicology Data at SOT 2026 Annual Meeting

Core Viewpoint - Oncotelic Therapeutics, through its subsidiary Sapu Nano, is presenting new findings on everolimus toxicology at the Society of Toxicology 2026 Annual Meeting, emphasizing the significance of tissue concentration in determining organ-specific toxicological outcomes [1][2][3]. Group 1: Presentation Details - The presentation titled "Everolimus Toxicology: Tissue Concentration Effects" will be featured during the Poster Session: ADME/Toxicokinetics I [2]. - Authors of the presentation include W. Chang, N. Chang, T. Hoque, and C. Lee from Sapu Nano, San Diego, CA [2]. - The findings aim to advance understanding of the relationship between tissue-level exposure of everolimus and its toxicological effects, moving beyond traditional plasma pharmacokinetics [2]. Group 2: Significance of Findings - The data presented highlight the importance of tissue pharmacokinetics in determining toxicity profiles for mTOR inhibitors like everolimus [3]. - These findings provide a foundation for developing improved drug delivery strategies, including intravenous and nanoparticle-based formulations that enhance control over biodistribution [3][4]. Group 3: Company Background - Oncotelic Therapeutics, originally formed as OXiGENE, Inc. in 1988, focuses on oncology drug development, particularly for rare pediatric cancers [6]. - The company has a joint venture for Diffuse Intrinsic Pontine Glioma (DIPG) and is also involved in developing treatments for melanoma and Acute Myeloid Leukemia (AML) [6]. - Sapu Nano is dedicated to developing next-generation nanomedicine platforms aimed at improving drug delivery and enhancing therapeutic indices [5].